Abstract: Pemetrexed, a multitargeting antifolate cytotoxic drug, plays a leading role in front-line chemotherapy for patients with advanced non-squamous non-small-cell lung cancer (NSCLC). Following its approval as second-line monotherapy for locally advanced or metastatic non-squamous NSCLC, pemetrexed has established itself as the first-line regimen in combination with cisplatin, and its powerful antitumor effects and less cumulative toxicities were then taken advantage of in the JMEN and PARAMOUNT trials, respectively, to pioneer a new treatment strategy of switch and continuation maintenance monotherapy. These developments have brought about a marked paradigm shift, and made pemetrexed indispensable in the treatment for non-squamous NSCLC. So far, only three drugs have been approved for maintenance therapy; pemetrexed both by switch and continuation maintenance, erlotinib by switch maintenance, and bevacizumab by continuation maintenance. Compared with observation alone after defined cycles of the first-line chemotherapy, subsequent pemetrexed maintenance therapy has provided significantly longer survival and infrequent severe adverse events. The cost-effectiveness of pemetrexed maintenance therapy is controversial, as well as the other two maintenance drugs, bevacizumab and erlotinib. The latest attractive attention is a combination maintenance therapy. We may have to consider epidermal growth factor receptor (EGFR) mutation status for selection of a combination pattern. A combination maintenance therapy of pemetrexed plus bevacizumab is potential for patients with wild-type EGFR status, while a EGFR tyrosine kinase inhibitorcontaining combination is promising for patients with active EGFR mutation status. Pemetrexed will be a pivotal drug when a combination maintenance therapy is used in practice. For future maintenance therapy, we need to explore reliable predictive selection or exclusion markers that can predict who will really benefit from maintenance therapy.
Introduction
Lung cancer is a leading cause of cancer mortality and accounted for 1.59 deaths worldwide in 2012. 1 Histopathologically, lung cancer is divided broadly into two groups, ie, non-small-cell lung cancer (NSCLC) and small cell lung cancer. The former accounts for 80%-85% of all lung cancer cases, and is further divided into several subgroups, ie, adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and others. Most patients with NSCLC are diagnosed when their disease has already advanced locally or metastasized systemically. For inoperable patients with good performance status, chemotherapy is a standard treatment option.
Pemetrexed (Alimta ® , Eli Lilly, Indianapolis, IN, USA) is a multitargeted antifolate drug that inhibits replication and survival of cancer cells by disrupting folate-dependent metabolic processes. During the past decade, this drug has come to have a leading role in front-line chemotherapy for patients with advanced non-squamous NSCLC, owing to its antitumor effects and mild toxicity.
When combined with platinum in a first-line regimen for non-squamous NSCLC, pemetrexed is superior or similar in efficacy and superior in toxicities to other third-generation antitumor drugs. There were three randomized Phase III studies that compared various endpoints between platinum plus pemetrexed and conventional platinum-based doublets in NSCLC (Table 1) . [2] [3] [4] Among them, a milestone was the JMDB trial, 4 in which cisplatin plus pemetrexed showed noninferiority in overall survival (OS) and better tolerability compared with cisplatin plus gemcitabine. In addition, this trial also indicated a histological difference in efficacy. Namely, pemetrexed improved OS for patients with non-squamous histology, but failed for patients with squamous histology. These results led to the approval of cisplatin plus pemetrexed for patients with advanced non-squamous NSCLC as a first-line regimen by the European Medicines Agency in April 2008 and by the US Food and Drug Administration in September 2008. Health-related quality of life and survival without grade 3 or 4 toxicity (SWT) was compared between carboplatin plus pemetrexed and carboplatin plus gemcitabine in a Norwegian study and between carboplatin plus pemetrexed and carboplatin plus docetaxel in a multinational study, respectively. 2, 3 Compared with control regimens, carboplatin plus pemetrexed provided similar health-related quality of life and OS in the Norwegian study, 2 and longer SWT but similar OS in the other study. 3 In addition, platinum plus pemetrexed was generally less toxic, except for severe nausea, 4 and generally caused less frequent severe leukopenia and neutropenia than control regimens in all studies (Table 2) . [2] [3] [4] Concerning cost-effectiveness, the platinum plus pemetrexed doublet is considered to be cost-effective, particularly in patients with non-squamous NSCLC histology (Table 3 ). There were two US studies with different approaches for first-line platinum plus pemetrexed. 5, 6 Based on a state transition model, Klein et al concluded that cisplatin plus pemetrexed was a cost-effective treatment for patients with non-squamous NSCLC when compared with cisplatin plus gemcitabine and a commonly mentioned but unwarranted threshold of US $100,000 per life-year gained (LYG) in the USA. 5 Compared with a first-line combination of cisplatin plus gemcitabine, cisplatin plus pemetrexed led to an incremental cost per LYG of US $104,577 for patients with NSCLC regardless of histological subtype, but a cost of US $83,537 for patients with non-squamous NSCLC. 
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Pemetrexed as a maintenance strategy Thus, considering the effect of prolongation of survival by the pemetrexed-containing regimen, pemetrexed was expensive but within the allowance. Based on indirect comparisons of the following three regimens in different studies because of no available head-to-head data, platinum plus pemetrexed was also considered more cost-effective than a triplet of bevacizumab combined with carboplatin plus paclitaxel, but controversial when compared with a doublet of carboplatin plus paclitaxel, as the pemetrexedcontaining regimen was more costly but more effective than carboplatin plus paclitaxel. 5, 6 In September 2009, the National Institute for Health and Clinical Excellence (NICE) in the UK recommended pemetrexed in combination with cisplatin as an option for the first-line treatment of patients with non-squamous NSCLC, using the single technology appraisal process and based on the Evidence Review Group's exploratory analysis indicating that the incremental costeffectiveness ratios (ICERs) for cisplatin plus pemetrexed compared with cisplatin plus gemcitabine were between £20,000 and £30,000 per quality-adjusted life-year (QALY) gained for non-squamous NSCLC and between £17,000 and £25,000 per QALY for adenocarcinoma or large-cell carcinoma, all under the willing-to-pay threshold of £30,000 per QALY gained. Options for maintenance therapy; continuation maintenance versus switch maintenance Maintenance therapy after 4-6 cycles of platinum-based induction chemotherapy is a standard first-line regimen for patients with advanced non-squamous NSCLC. Maintenance therapies are classified broadly into two types, ie, continuation maintenance and switch maintenance. The former is a continuation of one or two drugs used in the induction regimen and the latter involves introduction of an additional drug that was not used in the induction regimen. Switch maintenance can be understood as an early second-line therapy. Differences in efficacy between these two maintenance strategies remain unknown. A recent metaanalysis did not detect any significant differences in OS or progression-free survival (PFS) between these two maintenance strategies. 8 In contrast, another two meta-analyses showed favorable OS benefits for switch maintenance. 9, 10 In the study by Behera et al, switch maintenance provided significant benefit, both in PFS (hazard ratio [HR] 10 From the viewpoint of clinical practice, these two maintenance strategies are very different, especially at the time of transition from the induction phase to the maintenance phase. Most oncologists would hesitate to discontinue an effective and tolerable induction regimen and then introduce a new drug with unknown efficacy and adverse effects. Thus, continuation maintenance is more acceptable than switch maintenance. 
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Pemetrexed as a maintenance strategy in cycle 2) weekly for 6 of 8 weeks. Abbreviations: AUC, area under the curve; CDDP, cisplatin; GeM, gemcitabine; HR, hazard ratio; M, months; ND, not described; Obs, observation alone; OS, overall survival; PeP, primary endpoint; PD, progressive disease; PeM, pemetrexed; PFS, progression-free-survival; Plt, platinum; PTX, paclitaxel; RR, overall response rate; TTP, time to progressive disease; w PTX, weekly paclitaxel.
Currently, there are three drugs, comprising two molecular targeted drugs and one cytotoxic drug, approved as maintenance monotherapy after platinum-based induction chemotherapy: erlotinib (Tarceva ® , Hoffmann-La Roche Ltd, Basel, Switzerland), a reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), as switch maintenance for patients with any NSCLC histology; bevacizumab (Avastin ® , Hoffmann-La Roche Ltd), a humanized monoclonal antibody that inhibits vascular endothelial growth factor and thereby angiogenesis, as continuation maintenance after platinum-based and bevacizumab-containing triplet induction for patients with non-squamous NSCLC; and pemetrexed as both types of maintenance for patients with non-squamous NSCLC.
Efficacy, safety, and tolerability of pemetrexed maintenance therapy
Pemetrexed is the only successful cytotoxic drug in maintenance therapy. There are three cytotoxic drugs that have been tested as candidates of continuation maintenance in phase III trials, but they showed different results (Table 4) . Paclitaxel improved neither PFS nor OS, 11 gemcitabine prolonged only PFS but not OS, [12] [13] [14] and only pemetrexed successfully extended both PFS and OS. 15, 16 In addition, severe adverse effects were less frequent during the pemetrexed maintenance phase, compared indirectly with paclitaxel and gemcitabine maintenance (Table 5 ). Thus, pemetrexed had an advantage of less cumulative toxicity and better tolerability. a eQ5D index (eQ5D-i) and eQ5D-vAS (euro-QoL questionnaire) at 12 weeks during maintenance therapy. Abbreviations: Bev, bevacizumab; CBDCA, carboplatin; CDDP, cisplatin; G4PFS, progression-free survival without grade 4 adverse event; HR, hazard ratio; M, months; ND, not described; OS, overall survival; PD, progressive disease; PeM, pemetrexed; PeP, primary endpoint; PFS, progression-free survival; PTX, paclitaxel; QoL, quality of life.
Erlotinib switch maintenance has never been compared with pemetrexed switch or continuation maintenance in a head-to-head Phase III trial. Bevacizumab combined with carboplatin plus paclitaxel has been directly compared with pemetrexed continuation maintenance in two Phase III studies (Table 6) . 17, 18 These two studies, PRONOUNCE and ERACLE, defined unique primary endpoints of PFS without grade 4 adverse events 18 and difference in QoL, 17 respectively, instead of the usual efficacy parameters of PFS or OS. Thus, these studies provided little information with 
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Pemetrexed as a maintenance strategy regard to deciding which regimen is superior as the first-line regimen for patients with non-squamous NSCLC.
Cost-effectiveness of pemetrexed maintenance therapy
The cost-effectiveness of maintenance treatment with pemetrexed monotherapy is debatable (Table 7) . There were five pharmacoeconomic analyses from various countries addressing this problem. [19] [20] [21] [22] [23] Four analyses were based on a switch maintenance trial (JMEN), [19] [20] [21] [22] while the other was a continuation maintenance trial (PARAMOUNT). 23 Three of these analyses concluded that pemetrexed maintenance is not cost-effective, irrespective of switch and continuation. [21] [22] [23] In the pharmacoeconomic analyses from Japan, Switzerland, and the People's Republic of China, each willingness-to-pay threshold was assumed as ¥5-6 million per LYG (US $43,478-52,174 per LYG), 22 €72,000 per QALY gained (Swiss federal court decision, November 23, 2010), 21 and US $13,527 per QALY gained (3× the per capita gross domestic product), 23 respectively. All ICERs based on LYG or QALY were more than these thresholds. [21] [22] [23] The UK analysis also found that the most plausible ICER was £47,000 per QALY gained, which was above the standard NICE willingness-to-pay range (£20,000 to £30,000 per QALY). 19 Considering that maintenance treatment with pemetrexed fulfilled the end-of-life criteria, NICE in the UK optionally recommended switch maintenance by pemetrexed only for patients with non-squamous histology. 24 In contrast, NICE did not recommend continuation maintenance by pemetrexed because the most plausible ICER, approximately £74,500 per QALY gained, was higher than that normally considered to be cost-effective, even if the supplementary advice of NICE on end-of-life treatments was taken into consideration. 25 The US analysis indicated that pemetrexed may be considered cost-effective. 20 The ICER for pemetrexed to observation alone, ie, US $122,371, may not be cost-effective when compared with a commonly mentioned threshold of US $100,000 per LYG, but may be cost-effective when compared with a range of US $95,000 to US $264,000 per LYG, a recently revised plausible lower and upper bounds for cost-effectiveness decision rule in the USA. 26 Comparison of cost-effectiveness between different types of maintenance is more difficult because of a lack of head-tohead clinical trials. Three studies have indirectly compared direct medical costs between maintenance with pemetrexed and maintenance with another drug (Table 8) . 20, 27, 28 A US study showed that pemetrexed maintenance is more costeffective for patients with non-squamous NSCLC than erlotinib, because the ICER for pemetrexed versus erlotinib (US $150,260/LYG) is within the acceptable range of willingness to pay. 20 Another UK study also showed a clear advantage in favor of pemetrexed, ICER for erlotinib versus pemetrexed, £84,029/QALY gained. 27 In contrast, a European cross-market cost comparison showed that total monthly treatment costs per patient, including acquisition costs, administration costs, and costs of treating adverse events, were more reasonable for erlotinib than for pemetrexed, ie, €2,140 for erlotinib versus €3,453 for pemetrexed in France, €2,732 versus €5,534 in Germany, €1,518 versus €2,921 in Italy, and €2,048 versus €3,164 in Spain. 28 Thus, it remains unknown which maintenance strategy is the most cost-effective.
There were many study limitations in these pharmacoeconomic analyses; for example, a lack of clinical trials and detailed information about quality of life, imbalanced accrual in trials, and a variety of medical services among countries and territories. A Japanese study of direct medical cost by Tsuchiya et al 22 was based on clinical results of JMEN study 29 and Japanese health care system. Although the JMEN study included 32% of Asian population in pemetrexed switch maintenance group mainly from the People's Republic of China and Korea, no Japanese patient participated in this trial. The PARAMOUNT trial, undertaken in 93 center in 16 countries, included Asian population in only 4% of all cases. 30 Therefore, we Japanese and Asian can not refer to clinical results of this trial for a pharmacoeconomic study. There were three Japanese single-arm, Phase II studies evaluating a combination of carboplatin plus pemetrexed followed by pemetrexed maintenance for patients with non-squamous NSCLC. These trials provided an impressive median OS of more than 20 months not only from maintenance chemotherapy in patients who had received maintenance therapy 31, 32 but also from induction chemotherapy in all enrolled patients. 32, 33 In contrast, the JMEN and PARAMOUNT studies showed a median OS of 16.5 and 16.9 months, respectively, from induction chemotherapy for patients who had proceeded into the maintenance phase (Table 9) . 15, 16, 29 OS in the Japanese single-arm, Phase II studies was much longer (by approximately 4 months) than in the multinational randomized placebo-controlled studies. Thus, the Japanese medical economic study possibly underestimated pemetrexed maintenance when based on clinical data from other ethnic groups and countries. Further studies and discussions are warranted with regard to pemetrexed maintenance.
Future directions
A recent interesting challenge is doublet combination maintenance (Table 6) . [34] [35] [36] We may have to consider EGFR mutation 38 This study suggests that, for patients with active EGFR mutation status, combination of these two molecularly targeted drugs potentially yields a better survival benefit than erlotinib alone. We hope that this combination is beneficial in the maintenance setting, as well as in the first-line setting.
For patients with non-squamous NSCLC and wild-type or unknown EGFR mutation status, pemetrexed plus bevacizumab 
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Pemetrexed as a maintenance strategy Abbreviations: CBDCA, carboplatin; CDDP, cisplatin; M, month; Multi, multinational; ND, not described; NSCLC, non-small-cell lung cancer; OS, overall survival; PeM, pemetrexed; PFS, progression-free survival; Plt, platinum; R-p2, randomized phase ii; R-p3, randomized phase iii; S-p2, single-arm phase ii; SQ, squamous cell carcinoma.
is possibly promising. Compared with bevacizumab alone, continuation maintenance of pemetrexed plus bevacizumab significantly prolonged PFS by a median of 3.7 months, but did not achieve a significant improvement in OS, despite a difference of 3.9 months in median OS after four cycles of bevacizumab combined with cisplatin plus pemetrexed (AVAPERL). 35 Another Phase III study (PointBreak) showed that continuation maintenance of pemetrexed plus bevacizumab after an induction triplet of bevacizumab combined with carboplatin plus pemetrexed was similar in OS but significantly superior in PFS when compared with continuation maintenance of bevacizumab alone after bevacizumab combined with carboplatin plus paclitaxel. 36 Thus, even the combination of pemetrexed plus bevacizumab remains unable to show an OS benefit when compared with bevacizumab alone. Adverse effects of anemia, thrombocytopenia, and fatigue were significantly more frequent on combination maintenance than on bevacizumab alone in the PointBreak trial (Table 10) . 36 Benefit in terms of cost-effectiveness should be investigated for these combination maintenance therapies when their significant survival benefits are demonstrated, because these drugs are all very expensive.
For the future, we may need to narrow the core patients who are predicted to benefit from maintenance therapy with pemetrexed or other drugs. Hence, more clear-cut markers are required, such as EGFR mutation status for NSCLC. The most promising predictive biomarker of the efficacy of pemetrexed at this time is the thymidylate synthase expression level. Basic research is warranted to identify a reliable biomarker than can predict the clinical benefit of pemetrexed. These personalized therapies represent appropriate treatment options and result in cost savings when using expensive drugs. Investigation of selection or exclusion biomarkers is warranted.
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